瑞德西韦治疗住院儿童COVID-19的2/3期研究
这项2/3期开放标签试验评估了瑞德西韦在28天至17岁住院儿童中的安全性和药代动力学。53名参与者接受基于生理药代动力学模型确定的剂量,用药暴露与成人3期数据大致重叠但适度增加,未观察到新的安全性趋势,第10天62%康复。
要点
- 瑞德西韦在儿童中的暴露与成人相似但适度增加。
- 未观察到新的安全性趋势,但有小样本局限性。
- 第10天康复率62%,末次评估83%。
核心结论
- 在婴儿和儿童COVID-19患者中,所评估的瑞德西韦剂量提供的药物暴露与成人剂量相似。
- 在这项小样本研究中,未观察到新的安全性担忧。
研究设计与样本
- 这是一项2/3期开放标签试验,纳入28天至17岁因PCR确诊SARS-CoV-2感染住院的儿童。
- 参与者接受每日一次静脉瑞德西韦≤10天,剂量基于生理药代动力学模型确定。
- 共53名参与者,入组时COVID-19症状中位天数5天,住院中位天数1天。
主要发现
- 基础疾病包括肥胖19例(37%)、哮喘11例(21%)、心脏疾病11例(21%)。
- 瑞德西韦治疗中位持续时间5天(范围1-10天)。
- 两名参与者因不良事件(包括转氨酶升高)停药,两人基线时均有转氨酶升高。
- 治疗期间发生3例死亡(治疗后1例)。
- 与成人3期数据相比,儿童估计平均参数(AUCτ、Cmax、Cτ)大致重叠但适度增加:瑞德西韦33%-129%,GS-704277 37%-124%,GS-441524 0%-60%。
关键数值与推荐
- 剂量:≥40 kg者第1天200 mg,之后100 mg/天;≥28天且≥3至<40 kg者第1天5 mg/kg,之后2.5 mg/kg/天。
- 用药时长≤10天,每日一次静脉给药。
临床怎么用
- 对于住院儿童COVID-19患者,可考虑使用基于生理药代动力学模型确定的瑞德西韦剂量,其暴露与成人相似。
- 治疗期间需监测不良事件,尤其是转氨酶升高,基线异常者更需注意。
局限性
- 样本量小(53例),可能限制安全性结论的可靠性。
- 开放标签设计,无对照组。
- 缺乏长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Remdesivir decreases the risk of SARS-CoV-2 infection progressing to severe disease in adults. This study evaluated remdesivir safety and pharmacokinetics in infants and children. METHODS: This was a phase 2/3, open-label trial in children aged 28 days to 17 years hospitalized for polymerase chain reaction-confirmed SARS-CoV-2 infection. Participants received for ≤10 days once-daily intravenous remdesivir doses defined using physiologically based pharmacokinetic modeling (for ≥40 kg, 200 mg day 1, then 100 mg/day; for age ≥28 days and ≥3 to <40 kg, 5 mg/kg day 1, then 2.5 mg/kg/day). Sparse pharmacokinetic samples were analyzed using population-pharmacokinetic approaches for remdesivir and metabolites GS-704277 and GS-441524. RESULTS: Among 53 participants, at enrollment the median (Q1, Q3) number of days of COVID-19 symptoms was 5 (3, 7) and hospitalization was 1 (1, 3). Underlying conditions included obesity in 19 (37%), asthma in 11 (21%), and cardiac disorders in 11 (21%). Median duration of remdesivir treatment was 5 days (range, 1-10). Remdesivir treatment had no new apparent safety trends. Two participants discontinued treatment because of adverse events including elevated transaminases; both had elevated transaminases at baseline. Three deaths occurred during treatment (and 1 after). When compared with phase 3 adult data, estimated mean pediatric parameters (area under the concentration-time curve over 1 dosing interval, AUCτ, Cmax, and Cτ) were largely overlapping but modestly increased (remdesivir, 33%-129%; GS-704277, 37%-124%; GS-441524, 0%-60%). Recovery occurred for 62% of participants on day 10 and 83% at last assessment. CONCLUSIONS: In infants and children with COVID-19, the doses of remdesivir evaluated provided drug exposure similar to adult dosing. In this study with a small sample size, no new safety concerns were observed.
引用
- Ahmed A, Munoz FM, Muller WJ, et al. Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study. Pediatrics. 2024. PMID: 38332740. doi:10.1542/peds.2023-063775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。